In OSCC, the anti-TFRC antibody is suspected to block the internalization of transferrin into cancer cells, and the resulting transferrin deficiency might block the cell cycle and/or induce apoptotic cell death due to the potentially abnormal transferrin requirements of cancer cells 21. Here, TFRC is linked to cancer.